CoChat

In Vitro and In Vivo Evaluation of APX001A/APX001 and Other Gwt1 Inhibitors against Cryptococcus

Open access

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

Cryptococcal meningitis (CM), caused primarily by Cryptococcus neoformans , is uniformly fatal if not treated. Treatment options are limited, especially in resource-poor geographical regions, and mortality rates remain high despite current therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1128/aac.00523-18

Cites

Statistics

Figures

FIG 1 Efficacy of APX001 alone and in combination with FLC in a murine model of C. neoformans meningitis. Brain and lung burdens in mice were measured at 7 days postinfection with C. neoformans H99. Male CD-1 mice were infected with 5.9 × 104 CFU of C. neoformans strain H99 via the lateral tail vein. Treatment was initiated at about 1 h postinfection and continued for 7 days. APX001 was administered by oral gavage at a dose of 390 mg/kg thrice daily, with each dose being administered roughly 8 h apart. FLC (2 mg/ml; Sagent Pharmaceuticals, Schaumburg, IL) was administered at a dose of 80 mg/kg/day i.p. once daily. Fungal burden data were log10 transformed and evaluated using Kruskal-Wallis tests with Dunn's multiple-comparison test for post hoc analysis (Prism software, v5; GraphPad Software, Inc., San Diego, CA). A P value of ≤0.05 was considered statistically significant (*, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001). The 95% confidence interval (CI) is presented.
FIG 1 Efficacy of APX001 alone and in combination with FLC in a murine model of C. neoformans meningitis. Brain and lung burdens in mice were measured at 7 days postinfection with C. neoformans H99. Male CD-1 mice were infected with 5.9 × 104 CFU of C. neoformans strain H99 via the lateral tail vein. Treatment was initiated at about 1 h postinfection and continued for 7 days. APX001 was administered by oral gavage at a dose of 390 mg/kg thrice daily, with each dose being administered roughly 8 h apart. FLC (2 mg/ml; Sagent Pharmaceuticals, Schaumburg, IL) was administered at a dose of 80 mg/kg/day i.p. once daily. Fungal burden data were log10 transformed and evaluated using Kruskal-Wallis tests with Dunn's multiple-comparison test for post hoc analysis (Prism software, v5; GraphPad Software, Inc., San Diego, CA). A P value of ≤0.05 was considered statistically significant (*, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001). The 95% confidence interval (CI) is presented.CC BY · PubMed Central
FIG 2 Efficacy of APX compounds in a murine model of cryptococcal meningitis in conjunction with ABT administration. ABT at 100 mg/kg was administered orally to male CD-1 mice at 2 h prior to each APX compound dose. Mice were injected with 6.9 × 104 CFU of C. neoformans strain H99 per mouse via the lateral tail vein at time zero. Treatment with the APX compound was initiated at about 1 h postinfection by i.p. administration and continued for 7 days, with 100-mg/kg ABT being administered orally 2 h prior to each APX compound dose. The correction factors for the prodrug potencies versus the potencies of the active moieties were similar enough such that the same factor (1.3) was used for all APX compounds. Acute toxicity was observed on day 1 for APX2096 and on day 6 for APX2097, and therefore, the dose was reduced to 60 mg/kg for days 2 to 7 (APX2096) and day 7 (APX2097) for the surviving mice. The final numbers of surviving mice were 4 for the controls, 5 for APX001-treated mice, 3 to 5 for APX2096-treated mice, and 4 or 5 for APX2097. Fungal burden data were log10 transformed and evaluated using Kruskal-Wallis tests with Dunn's multiple-comparison test for post hoc analysis (Prism software, v5; GraphPad Software, Inc., San Diego, CA). A P value of ≤0.05 was considered statistically significant (*, P ≤ 0.05; **, P ≤ 0.01). The 95% confidence interval (CI) is presented.
FIG 2 Efficacy of APX compounds in a murine model of cryptococcal meningitis in conjunction with ABT administration. ABT at 100 mg/kg was administered orally to male CD-1 mice at 2 h prior to each APX compound dose. Mice were injected with 6.9 × 104 CFU of C. neoformans strain H99 per mouse via the lateral tail vein at time zero. Treatment with the APX compound was initiated at about 1 h postinfection by i.p. administration and continued for 7 days, with 100-mg/kg ABT being administered orally 2 h prior to each APX compound dose. The correction factors for the prodrug potencies versus the potencies of the active moieties were similar enough such that the same factor (1.3) was used for all APX compounds. Acute toxicity was observed on day 1 for APX2096 and on day 6 for APX2097, and therefore, the dose was reduced to 60 mg/kg for days 2 to 7 (APX2096) and day 7 (APX2097) for the surviving mice. The final numbers of surviving mice were 4 for the controls, 5 for APX001-treated mice, 3 to 5 for APX2096-treated mice, and 4 or 5 for APX2097. Fungal burden data were log10 transformed and evaluated using Kruskal-Wallis tests with Dunn's multiple-comparison test for post hoc analysis (Prism software, v5; GraphPad Software, Inc., San Diego, CA). A P value of ≤0.05 was considered statistically significant (*, P ≤ 0.05; **, P ≤ 0.01). The 95% confidence interval (CI) is presented.CC BY · PubMed Central
FIG 3 Dose-response of APX2096 and APX2097 in a murine model of cryptococcal meningitis in conjunction with ABT administration. ABT at 100 mg/kg was administered orally to male CD-1 mice at 2 h prior to each APX compound dose. Mice were injected with 4.8 × 104 CFU C. neoformans strain H99 per mouse via the lateral tail vein at time zero. Treatment with the APX compounds was initiated at 1 h postinfection by i.p. administration and continued for 7 days, with 100-mg/kg ABT being administered orally 2 h prior to each APX compound dose. The correction factors for prodrug potencies versus the potencies of the active moieties were similar enough such that the same factor (1.3) was used for all APX compounds. Fungal burden data were log10 transformed and evaluated using Kruskal-Wallis tests with Dunn's multiple-comparison test for post hoc analysis (Prism software, v5; GraphPad Software, Inc., San Diego, CA). For analysis of the fungal burden, the control mice that received ABT were used for comparisons to APX compound-treated groups receiving ABT, and the untreated control mice were used for comparisons to APX compound-treated groups that did not receive ABT. A P value of ≤0.05 was considered statistically significant (*, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001). The 95% confidence interval (CI) is presented.
FIG 3 Dose-response of APX2096 and APX2097 in a murine model of cryptococcal meningitis in conjunction with ABT administration. ABT at 100 mg/kg was administered orally to male CD-1 mice at 2 h prior to each APX compound dose. Mice were injected with 4.8 × 104 CFU C. neoformans strain H99 per mouse via the lateral tail vein at time zero. Treatment with the APX compounds was initiated at 1 h postinfection by i.p. administration and continued for 7 days, with 100-mg/kg ABT being administered orally 2 h prior to each APX compound dose. The correction factors for prodrug potencies versus the potencies of the active moieties were similar enough such that the same factor (1.3) was used for all APX compounds. Fungal burden data were log10 transformed and evaluated using Kruskal-Wallis tests with Dunn's multiple-comparison test for post hoc analysis (Prism software, v5; GraphPad Software, Inc., San Diego, CA). For analysis of the fungal burden, the control mice that received ABT were used for comparisons to APX compound-treated groups receiving ABT, and the untreated control mice were used for comparisons to APX compound-treated groups that did not receive ABT. A P value of ≤0.05 was considered statistically significant (*, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001). The 95% confidence interval (CI) is presented.CC BY · PubMed Central
FIG 4 Efficacy of APX2096 and AMB in a delayed-treatment model of cryptococcal meningitis. Male CD-1 mice were infected with 5.4 × 104 CFU per mouse via lateral tail vein injection. Treatment with 60-mg/kg APX2096, 3-mg/kg AMB, or the vehicle control was initiated 24 h after infection and continued daily for 7 days. A dose of 100-mg/kg ABT was administered orally 2 h prior to each APX2096 dose. Mice were sacrificed 24 h after the last dose, and the brain and left lung were homogenized and cultured for quantitative determination of the tissue burden (number of CFU per gram of tissue). Fungal burden data were log10 transformed and evaluated using Kruskal-Wallis tests with Dunn's multiple-comparison test for post hoc analysis (Prism software, v5; GraphPad Software, Inc., San Diego, CA). A P value of ≤0.05 was considered statistically significant (*, P ≤ 0.05; **, P ≤ 0.01). The 95% confidence interval (CI) is presented.
FIG 4 Efficacy of APX2096 and AMB in a delayed-treatment model of cryptococcal meningitis. Male CD-1 mice were infected with 5.4 × 104 CFU per mouse via lateral tail vein injection. Treatment with 60-mg/kg APX2096, 3-mg/kg AMB, or the vehicle control was initiated 24 h after infection and continued daily for 7 days. A dose of 100-mg/kg ABT was administered orally 2 h prior to each APX2096 dose. Mice were sacrificed 24 h after the last dose, and the brain and left lung were homogenized and cultured for quantitative determination of the tissue burden (number of CFU per gram of tissue). Fungal burden data were log10 transformed and evaluated using Kruskal-Wallis tests with Dunn's multiple-comparison test for post hoc analysis (Prism software, v5; GraphPad Software, Inc., San Diego, CA). A P value of ≤0.05 was considered statistically significant (*, P ≤ 0.05; **, P ≤ 0.01). The 95% confidence interval (CI) is presented.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 41 · Cited by 121

Research works printed but not linked: 8

  1. Hata K, Horii T, Miyazaki M, Watanabe NA. 2011. In vitro and in vivo antifungal activities of E1211, a water-soluble prodrug of E1210, abstr F1-1377. Abstr 51st Intersci Conf Antimicrob Agents Chemother, Chicago, IL. American Society for Microbiology, Washington, DC.
  2. Zhao Y, Lee M, Lee A, Paderu P, Park S, Perlin DS. 2018. APX001 is effective against echinocandin and multi-drug resistant Candida isolates. Abstr 28th ECCMID, Madrid, Spain.
  3. Watanabe NA, Horii T, Miyazaki M, Hata K. 2011. In vitro activity of E1210 and in vivo activity of E1211, a water-soluble prodrug of E1210, in combination with other antifungals, abstr F1-1378. Abstr 51st Intersci Conf Antimicrob Agents Chemother, Chicago, IL. American Society for Microbiology, Washington, DC.
  4. Gebremariam T, Alkhazraji S, Alqarihi A, Wiederhold NP, Shaw KJ, Patterson TF, Filler SG, Ibrahim A. 2017. APX001 protects immunosuppressed mice from Rhizopus delemar infection, poster 1521. Abstr IDWeek 2017, San Diego, CA.
  5. Schell WA, Giamberardino C, Shaw KJ, Perfect JR. 2017. Efficacy of oral APX001 in a murine model of cryptococcal meningitis, poster 1529. Abstr IDWeek 2017, San Diego, CA.
  6. Mansbach RS, Shaw KJ, Hodges MR, Coleman S, Fitzsimmons ME. 2017. Absorption, distribution, and excretion of [14C]-APX001 after single-dose administration to rats and monkeys, poster 1513. Abstr IDWeek 2017, San Diego, CA.
  7. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard, 3rd ed. CLSI document M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
  8. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard, 2nd ed. CLSI document M38-A2. Clinical and Laboratory Standards Institute, Wayne, PA.

Metadata

Authors
Shaw, K. J., Schell, W. A., Covel, J., Duboc, G., Giamberardino, C., Kapoor, M., Moloney, M., Soltow, Q. A., Tenor, J. L., Toffaletti, D. L., Trzoss, M., Webb, P., & Perfect, J. R.
Affiliations
  • Amplyx Pharmaceuticals (United States) (US)
  • Duke Medical Center (US)
  • Division of Infectious Diseases, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA
Corresponding author
Shaw, Karen Joy
Venue
Antimicrobial Agents and Chemotherapy
Published
2018-08
Volume
62
Issue
8
ISSN
  • 0066-4804 (ISSN-L)
  • 1098-6596
OpenAlex
W2805470919
Cited by
121
References
41
Citations by year
2026: 12 · 2025: 10 · 2024: 17 · 2023: 17 · 2022: 12 · 2021: 18 · 2020: 14 · 2019: 17 · 2018: 4
FWCI
10.34
Type
journal article
Language
en
Open access
Licence
Locations
  • Antimicrobial Agents and Chemotherapy (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
National Institute of Allergy and Infectious Diseases (R01AI073896, P01AI104533)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
Keywords
Cryptococcus, cryptococcal meningitis, antifungal agents, fungal cell wall biosynthesis, in vitro antifungal activity, in vivo antifungal activity
MeSH terms
Administration, Oral, Amidohydrolases, Aminopyridines, Animals, Antifungal Agents, Brain, Cryptococcus neoformans, Disease Models, Animal, Dose-Response Relationship, Drug, Drug Combinations, Drug Synergism, Fungal Proteins, Humans, Injections, Intraperitoneal, Isoxazoles, Lung, Male, Microbial Sensitivity Tests, Organophosphates, Prodrugs, Fluconazole, Meningitis, Cryptococcal, Mice, Cryptococcus gattii

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: In Vitro and In Vivo Evaluation of APX001A/APX001 and Other Gwt1 Inhibitors against Cryptococcus. https://app.cochat.ai/papers/10.1128/aac.00523-18
The paper
Shaw, K. J., Schell, W. A., Covel, J., Duboc, G., Giamberardino, C., Kapoor, M., Moloney, M., Soltow, Q. A., Tenor, J. L., Toffaletti, D. L., Trzoss, M., Webb, P., & Perfect, J. R. (2018). In Vitro and In Vivo Evaluation of APX001A/APX001 and Other Gwt1 Inhibitors against Cryptococcus. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00523-18

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.